Maiwald
Sponsored
Sponsored
-
Sponsored by MaiwaldKerstin Wolff of Maiwald reports on a proposal that supports the use of some plants generated by new genomic techniques but opposes patents for all plants obtained by such means
-
Sponsored by MaiwaldEva Ehlich and Anja Fux of Maiwald summarise an EPO board ruling relating to substances and compositions in the context of medical use claims and how it could affect applicants’ portfolio strategies
-
Sponsored by MaiwaldWhile some observers are of the view that an Enlarged Board of Appeal ruling failed to provide sufficient clarity, Eva Ehlich and Anja Fux of Maiwald say the picture concerning post-published evidence is becoming clearer
-
Sponsored by MaiwaldSusanna Heurung of Maiwald welcomes a decision by the Board of Appeal regarding the extension of a grace period for use where the applicant’s bad faith was obvious
-
Sponsored by MaiwaldIn concluding a two-part series on springboard injunctions, Marco Stief of Maiwald takes a deeper dive to explain their requirements, review case law, and examine their relevance in the pharmaceutical and life sciences sectors
-
Sponsored by MaiwaldIn the first of two articles on the springboard doctrine, Marco Stief of Maiwald explains how the protective effect of a patent can continue to have an impact after the term of protection has ended